Hybrids of 4-hydroxy derivatives of goniothalamin ... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Hybrids of 4-hydroxy derivatives of goniothalamin and piplartine bearing a diester or a 1,2,3-triazole linker as antiproliferative agents

Full text
Author(s):
Grigolo, Thiago A. [1] ; Braga, Carolyne B. [1] ; Ornelas, Catia [1] ; Russowsky, Dennis [2] ; Ferreira-Silva, Guilherme A. [3] ; Ionta, Marisa [3] ; Pilli, Ronaldo A. [1]
Total Authors: 7
Affiliation:
[1] Univ Estadual Campinas, Inst Chem, Dept Organ Chem, UNICAMP, BR-13083970 Campinas, SP - Brazil
[2] Univ Fed Rio Grande do Sul, Inst Chem, BR-91501970 Porto Alegre, RS - Brazil
[3] Univ Fed Alfenas, Inst Biomed Sci, UNIFAL MG, BR-37130001 Alfenas, MG - Brazil
Total Affiliations: 3
Document type: Journal article
Source: BIOORGANIC CHEMISTRY; v. 116, NOV 2021.
Web of Science Citations: 0
Abstract

A library of nine hybrids of 4-hydroxygoniothalamin (2), 4-hydroxypiplartine (4), monastrol (5) and oxomonastrol (6) was prepared via a modular synthetic route with a diester or a 1,2,3-triazole as linkers. The compounds were assayed against a panel of human cancer cell lines, including MCF-7 (breast adenocarcinoma), HeLa (cervical adenocarcinoma), Caco-2 (colorectal adenocarcinoma) and PC3 (prostate adenocarcinoma), as well as against normal breast (MCF10A) and prostate (PNT2) cells. In general, hybrids with an ester linker containing 4-hydroxypiplartine (4) were more potent than the corresponding hybrids with 4-hydroxygoniothalamin (2). On the other hand, compounds presenting the 1,2,3-triazole linker displayed enhanced cytotoxicity and selectivity when compared to their corresponding hybrids with the diester linker. The 4-hydroxypiplartinebased hybrids 12 and 22 displayed high cytotoxicity (IC50 values below 10 mu M) against all cancer cells studied, especially in MCF-7 cells with IC50 values of 1.7 +/- 0.1 and 1.6 +/- 0.9 mu M, respectively. Furthermore, the 4hydroxygoniothalamin-monastrol hybrid (compound 21) and the 4-hydroxypiplartine-oxo-monastrol hybrid (compound 25), both bearing a 1,2,3-triazole linker, displayed high selectivity and potency towards breast cancer cell line (MCF-7 vs. MCF10 cells, selectivity index = 15.8 and 7.1, respectively), while the 4-hydroxypiplartine -4-hydroxymethylgoniothalamin hybrid with a diester linker (compound 33) showed high selectivity towards melanoma cancer cells (selectivity index = 9.6). Antiproliferative and pro-apoptotic potential of compounds 12 and 22 against MCF-7 cancer cells were further investigated. Cell cycle studies revealed increased G2/ M population in MCF-7 cultures as well as reduced G0/G1 population compared to the control groups indicating cell cycle arrest in G2/M phase. In addition, the frequency of positive cells for annexin V was higher in treated samples suggesting that compounds 12 and 22 induce apoptosis in estrogen-positive MCF-7 cells. (AU)

FAPESP's process: 17/06146-8 - Development of nanocarriers based on dendrimers and polymer nanoparticles for selective delivery of goniothalamin, piplartine and Monastrol
Grantee:Carolyne Brustolin Braga
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 18/02093-0 - Development of new nanomaterials for nanomedicine applications
Grantee:Cátia Cristina Capêlo Ornelas Megiatto
Support Opportunities: Regular Research Grants
FAPESP's process: 13/07607-8 - OCRC - Obesity and Comorbidities Research Center
Grantee:Licio Augusto Velloso
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 19/13104-5 - Planning and synthesis of inhibitors based on biological targets: the case of neglected kinases
Grantee:Ronaldo Aloise Pilli
Support Opportunities: Regular Research Grants